BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas

Chimeric somatostatin/dopamine compounds such as BIM-23A760, an sst2/sst5/D(2) receptors-agonist, have emerged as promising new approaches to treat pituitary adenomas. However, information on direct in vitro effects of BIM-23A760 in normal and tumoral pituitaries remains incomplete. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibáñez-Costa, Alejandro, López-Sánchez, Laura M., Gahete, Manuel D., Rivero-Cortés, Esther, Vázquez-Borrego, Mari C., Gálvez, María A., de la Riva, Andrés, Venegas-Moreno, Eva, Jiménez-Reina, Luis, Moreno-Carazo, Alberto, Tinahones, Francisco J., Maraver-Selfa, Silvia, Japón, Miguel A., García-Arnés, Juan A., Soto-Moreno, Alfonso, Webb, Susan M., Kineman, Rhonda D., Culler, Michael D., Castaño, Justo P., Luque, Raúl M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299479/
https://www.ncbi.nlm.nih.gov/pubmed/28181484
http://dx.doi.org/10.1038/srep42002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299479/
https://www.ncbi.nlm.nih.gov/pubmed/28181484
http://dx.doi.org/10.1038/srep42002

Ejemplares similares